Key takeaways Semaglutide is the active ingredient in Ozempic, an FDA-approved injection to lower blood sugar in the treatment of Type 2 diabetes and reduce cardiovascular and kidney risk in certain populations
Hims, as the company is often referred to, has become one of the most prominent public faces of compounded semaglutide, offering it in more than 30 states and spending nearly $145 million in a single quarter on marketing its drugs, which include injections with the same active ingredient as Ozempic and Wegovy alongside other weight loss offerings that have attracted tens of thousands of customers
New anti-RNS and -RCS products for cosmetic treatment
If a dose of a once-weekly GLP-1 medication is missed, patients should follow product-specific guidance
At 0.25mg weekly, one vial lasts 12 weeks
With other synthetic peptide medications, the effects taper off when someone stops taking it